Tucson’s SynCardia wins OK for key heart study

Desert Angels portfolio company, Tucson-based SynCardia Systems Inc. has received approval from the U.S. Food and Drug Administration to conduct a clinical study of the company’s temporary Total Artificial Heart for permanent use as so-called “destination therapy.” The FDA approved an Investigational Device Exemption application to allow SynCardia to study the heart’s use in 19 patients who do not qualify for a donor heart transplant.

Click here for the full article